[go: up one dir, main page]

WO2025124760A1 - Traitement de la sous-population de patients atteints de polyarthrite rhumatoïde - Google Patents

Traitement de la sous-population de patients atteints de polyarthrite rhumatoïde Download PDF

Info

Publication number
WO2025124760A1
WO2025124760A1 PCT/EP2024/075319 EP2024075319W WO2025124760A1 WO 2025124760 A1 WO2025124760 A1 WO 2025124760A1 EP 2024075319 W EP2024075319 W EP 2024075319W WO 2025124760 A1 WO2025124760 A1 WO 2025124760A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
combination
acid
use according
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2024/075319
Other languages
English (en)
Inventor
Thomas Boesen
Thomas Engelbrecht Nordkild Jonassen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synact Pharma ApS
Original Assignee
Synact Pharma ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synact Pharma ApS filed Critical Synact Pharma ApS
Publication of WO2025124760A1 publication Critical patent/WO2025124760A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Definitions

  • the present invention relates to a compound of formula (I), including tautomeric and stereoisomeric forms thereof, or a pharmaceutically acceptable derivative thereof, for use in the treatment of treatment-naive rheumatoid arthritis, wherein said compound is to be administered with methotrexate (MTX) to a patient subpopulation with active systemic inflammation.
  • MTX methotrexate
  • said patient subpopulation encompass subjects who are diagnosed with moderate to severe rheumatoid arthritis within 6 months prior to treatment initiation. This patient subpopulation has demonstrated consistent response to the disclosed therapy across several outcome measures.
  • An arthritic disease is a condition that implies damage or inflammation in one or more joints.
  • the condition often presents with pain, swelling, heat, redness and limitation of movement.
  • arthritic disorders There are many different forms of arthritic disorders, the most common types being osteoarthritis and rheumatoid arthritis.
  • Rheumatoid arthritis is an autoimmune disorder that primarily affects joints and between 0.5-1% of adults in the developed world are affected by RA. While the cause of rheumatoid arthritis is not clear, it is believed to involve a combination of genetic and environmental factors.
  • the goal of current treatments is to reduce pain and inflammation to improve the quality of life of the patients suffering from the condition.
  • DMARDs Disease-modifying antirheumatic drugs
  • MTX methotrexate
  • MC1R-MC5R Melanocortin (MC) receptors
  • GPCRs G protein-coupled receptors
  • MC1R regulates UV light-induced skin tanning and other immune responses because of its expression on leukocytes.
  • MC2R regulates cortisol production on the adrenal glands, whereas MC5R plays a role on exocrine glands secretions.
  • MC3R and MC4R exert non-redundant functions on energy homeostasis in addition to specific anti- inflammatory roles; whereas MC3R activation is particularly protective for joint inflammation such as arthritis, MC4R provides neuroprotection in brain inflammation.
  • Peripheral MC1 R and MC3R can be pharmacologically activated to induce antiinflammation.
  • the endogenous agonist a-melanocyte-stimulating hormone (aMSH) is released by immune cells to counterbalance proinflammatory signals, thus preventing excessive tissue damage.
  • aMSH a-melanocyte-stimulating hormone
  • therapeutics targeting MC1 R and MC3R act by mimicking the body’s own protective resources and might be characterized by a lighter burden of side effects.
  • the small molecule AP1189 or resomelagon (E)-N-trans- ⁇ 3-[' ⁇ -(2-nitrophenyl)-1 H- pyrrol-2-yl]-allylidene ⁇ -aminoguanidium) is a biased agonist at receptors MC1 R and MC3R with anti-inflammatory properties together with a lack of effect on melanogenesis.
  • oral AP1189 elicits anti-inflammatory actions in peritonitis and accelerated the resolution phase, and afforded significant reduction of macroscopic and histological parameters of joint disruption in experimental inflammatory arthritis.
  • a synergistic effect of AP1189 and MTX in a mouse model of arthritis has been demonstrated (WO 2020/229297).
  • HAQ-DI HAQ- disability index
  • One aspect of the disclosure provides for a compound of formula (I)
  • formula (I) including tautomeric and stereoisomeric forms thereof; or a pharmaceutically acceptable derivative thereof, for use in the treatment of rheumatoid arthritis in a treatment-naive subject having a C- Reactive Protein (CRP) level of >3 mg/L, wherein said compound is administered with methotrexate (MTX).
  • CRP C- Reactive Protein
  • MTX methotrexate
  • CRP C- Reactive Protein
  • said rheumatoid arthritis is severe active rheumatoid arthritis, such as rheumatoid arthritis with a CDAI > 22 and/or a DAS28 score of above 5.1 .
  • said subject is diagnosed with rheumatoid arthritis within 6 months prior to treatment initiation.
  • said compound is E-/V-trans- ⁇ 3-[1-(2-nitrophenyl)-1 H-pyrrol-2-yl]- allylidenej-aminoguanidine (AP1189/resomelagon), or a pharmaceutically acceptable derivative thereof, such as a pharmaceutically acceptable salt thereof.
  • said compound is E-/V-trans- ⁇ 3-[1-(2-nitrophenyl)-1 H-pyrrol-2-yl]- allylidenej-aminoguanidinium acetate.
  • pharmaceutically acceptable derivative in the present context includes pharmaceutically acceptable salts, which indicate a salt which is not harmful to the patient.
  • Such salts include pharmaceutically acceptable basic or acid addition salts as well as pharmaceutically acceptable metal salts, ammonium salts and alkylated ammonium salts.
  • a pharmaceutically acceptable derivative further includes esters, solvates and prodrugs, or other precursors of a compound which may be biologically metabolized into the active compound, or crystal forms of a compound.
  • acid addition salt is intended to include “pharmaceutically acceptable acid addition salt” which indicates salts which are not harmful to the patient.
  • Acid addition salts include salts of inorganic acids as well as organic acids. Examples of pharmaceutically acceptable inorganic or organic acid addition salts include the pharmaceutically acceptable salts listed in J. Pharm. Sci. 66, 2, (1977) which is incorporated herein by reference.
  • Reference to AP1189 and a pharmaceutically acceptable salt of AP1189 (E)-N-[1-(2- nitrophenyl)-1-H-pyrrole-2-yl-allylideneamino]-guanidine) including tautomeric and isomeric forms thereof, is meant to encompass amorphous forms and well as any polymorphic (crystalline) forms of AP1189 and its salts.
  • Polymorphic forms of pharmaceutically acceptable salts of AP1189 are disclosed in WO 2022/268814.
  • the E, trans stereoisomer of AP1189 is known by the INN resomelagon.
  • terapéuticaally effective amount of a compound as used herein refers to an amount sufficient to cure, alleviate, prevent, reduce the risk of, or partially arrest the clinical manifestations of a given disease or disorder and its complications. An amount adequate to accomplish this is defined as “therapeutically effective amount”. Effective amounts for each purpose will depend on the severity of the disease or injury as well as the weight and general state of the subject. It will be understood that determining an appropriate dosage may be achieved using routine experimentation, by constructing a matrix of values and testing different points in the matrix, which is all within the ordinary skills of a trained physician or veterinary. ‘Amount’ and ‘dosage’ may be used interchangeably herein.
  • “approximately” and “about” as referred herein are synonymous.
  • “approximately” and “about” refer to the recited amount, value, or duration ⁇ 5%, ⁇ 4.5%, ⁇ 4%, ⁇ 3.5%, ⁇ 3%, ⁇ 2.5%, ⁇ 2%, ⁇ 1.75%, ⁇ 1.5%, ⁇ 1.25%, ⁇ 1 %, ⁇ 0.9%, ⁇ 0.8%, ⁇ 0.7%, ⁇ 0.6%, ⁇ 0.5% ⁇ 0.4%, ⁇ 0.3%, ⁇ 0.2%, ⁇ 0.1 %, ⁇ 0.09%, ⁇ 0.08%, ⁇ 0.07%, ⁇ 0.06%, ⁇ 0.05%, ⁇ 0.04%, ⁇ 0.03%, ⁇ 0.02%, or ⁇ 0.01 %.
  • “approximately” and “about” refer to the listed amount, value, or duration ⁇ 2.5%, ⁇ 2%, ⁇ 1.75%, ⁇ 1.5%, ⁇ 1.25%, ⁇ 1%, ⁇ 0.9%, ⁇ 0.8%, ⁇ 0.7%, ⁇ 0.6%, ⁇ 0.5%. In one embodiment, “approximately” and “about” refer to the listed amount, value, or duration ⁇ 1 %. In one embodiment, “approximately” and “about” refer to the listed amount, value, or duration ⁇ 0.5%. In one embodiment, “approximately” and “about” refer to the listed amount, value, or duration ⁇ 0.1%.
  • the terms “approximately” and “about” as referred herein refer to the recited amount or dosage ⁇ 10%, ⁇ 9%, ⁇ 8%, ⁇ 7%, ⁇ 6%, ⁇ 5%, ⁇ 4%, ⁇ 3%, ⁇ 2%, ⁇ 1.5%, ⁇ 1 %, ⁇ 0.5%.
  • treatment refers to the management and care of a patient for the purpose of combating a condition, disease or disorder.
  • the term is intended to include the full spectrum of treatments for a given condition from which the patient or subject is suffering.
  • the patient to be treated is preferably a mammal, in particular a human being. Treatment of animals, such as mice, rats, dogs, cats, horses, cows, sheep and pigs, is, however, also within the scope of the present context.
  • the patients to be treated can be of various ages.
  • subject’ and ‘patient’ may be used interchangeably herein.
  • remission refers to reduction or disappearance of the signs and symptoms of the arthritic disease.
  • the remission can be temporary or permanent. Partial remission is a reduction in the signs and symptoms of the arthritic disease, while complete remission is understood herein as a disappearance of the signs and symptoms of the arthritic disease.
  • compound of the disclosure is meant the compound of formula (I), for example, ⁇ 3- [1-(2-nitrophenyl)-1 H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidine and (E)-/V-frans- ⁇ 3-[1-(2- nitrophenyl)-1 H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidine, including a pharmaceutically acceptable salt thereof.
  • a subject having active systemic inflammation means that the subject has active systemic inflammation before or at the beginning of the disclosed treatment. The subject need not necessarily continue to have active systemic inflammation throughout treatment, at the end of the treatment, or after the treatment.
  • a subject having active systemic inflammation is characterized by a CRP level of >3 mg/L.
  • a subject having active systemic inflammation is characterized by a CRP level of >3 mg/L in blood, such as in plasma or serum.
  • Minor CRP elevation refers to levels between 0.3 mg/l and 1.0 mg/l. This can occur in people who are sedentary, pregnant, or living with a chronic condition, such as diabetes. Mild infections such as the common cold may also trigger these elevations. Moderate CRP elevation refers to levels between 1.0 m/dl and 10.0 mg/l, which can signal a more significant issue. A moderate elevation may be due to acute inflammation from an infection or chronic inflammation from a serious disease, such as RA or heart disease. Results equal to or greater than 8 mg/L or 10 mg/L are considered high or as marked elevation.
  • CRP C- Reactive Protein
  • MTX methotrexate
  • a compound of formula (I) formula (I) including tautomeric and stereoisomeric forms thereof; or a pharmaceutically acceptable derivative thereof, for use in the treatment of rheumatoid arthritis in a treatment-naive subject with a C- Reactive Protein (CRP) level of >3 mg/L.
  • CRP C- Reactive Protein
  • One embodiment of the present disclosure provides for a use of a combination of methotrexate and the compound of formula (I), including tautomeric and stereoisomeric forms thereof; or a pharmaceutically acceptable derivative thereof, for the manufacture of a medicament for the treatment of in a treatment-naive subject having a C-Reactive Protein (CRP) level of >3 mg/L.
  • CRP C-Reactive Protein
  • Treatment-naive in the present context means that said subject has not yet been treated for said rheumatoid arthritis, such as has not yet been treated prior to initiation of the claimed therapy such as prior to initiation of treatment with AP1189; in particular said subject has not yet been treated with a Disease-modifying antirheumatic drug.
  • said subject has not yet been treated with methotrexate, such as wherein said subject has not yet been treated with methotrexate prior to initiation of treatment with AP1189.
  • said treatment-naive subject is DMARD treatment-naive.
  • DMARDs include conventional synthetic DMARDs, such as methotrexate; biological therapies such as adalimumab; and targeted synthetic DMARDs, such as the JAK inhibitors baricitinib and tofacitinib.
  • said treatment- naive subject is naive to methotrexate treatment prior to initiating treatment with the compound of the present disclosure.
  • the subject with rheumatoid arthritis has not received MTX prior to treatment with the compound of the present disclosure.
  • the subject with rheumatoid arthritis is about to start up-titration with methotrexate.
  • treatment with said compound occurs concurrently with the initiation of treatment with methotrexate. In one embodiment treatment with said compound occurs concurrently with the initiation of dosing with methotrexate.
  • the treatment with MTX and the compound of the disclosure is initiated essentially at the same time.
  • the treatment with MTX and the compound of the disclosure is initiated simultaneously.
  • the subject has active systemic inflammation.
  • the active systemic inflammation is characterized by a CRP level of >3 mg/L.
  • the active systemic inflammation is characterized by a baseline CRP level of >3 mg/L.
  • the CRP level is measured in a subject’s blood; usually plasma or serum. Usually a CRP test requires only blood drawn from a vein.
  • the subject has elevated CRP, such as an elevated CRP of >3 mg/L.
  • said treatment-naive subject having a CRP level of >3 mg/L such as having a CRP level of >3 mg/L at baseline, has a CRP level of >3 mg/L in blood.
  • said subject has a CRP level of >3 mg/L in serum.
  • said subject has a CRP level of >3 mg/L in plasma.
  • CRP C- Reactive Protein
  • a subject having a baseline CRP level of >3 mg/L is a subject having a baseline CRP > 3 mg/L prior to treatment initiation.
  • a subject having a baseline CRP level of >3 mg/L is a subject having a baseline a CRP > 3 mg/L at treatment initiation, such as at the start of treatment.
  • Treatment initiation and ‘at the start of treatment’ refers to the treatment of the present disclosure, such as treatment with a compound of the present disclosure alone and in combi nation with MTX.
  • a subject having a baseline CRP level of >3 mg/L is a subject having a CRP > 3 mg/L at the first day of treatment. In one embodiment a subject having a baseline CRP level of >3 mg/L is a subject having a CRP > 3 mg/L at the first day of treatment with a compound of the present disclosure.
  • the present disclosure provides a compound of formula (I), including tautomeric and stereoisomeric forms thereof, or a pharmaceutically acceptable derivative or salt thereof, for use in the treatment of moderate to severe rheumatoid arthritis in a treatment-naive subject having a CRP level of >3 mg/L, wherein said compound is to be administered with methotrexate (MTX).
  • MTX methotrexate
  • said rheumatoid arthritis is moderate rheumatoid arthritis.
  • said rheumatoid arthritis is rheumatoid arthritis with a CDAI (Clinical disease activity score) score of between 10 and ⁇ 22; such as moderate rheumatoid arthritis with a CDAI score of between 10 and ⁇ 22.
  • CDAI Cosmetic disease activity score
  • said rheumatoid arthritis is rheumatoid arthritis with a DAS28 score of between 3.2 and ⁇ 5; such as moderate rheumatoid arthritis with a DAS28 score of between 3.2 and ⁇ 5.
  • the present disclosure provides a compound of formula (I), including tautomeric and stereoisomeric forms thereof, or a pharmaceutically acceptable derivative or salt thereof, for use in the treatment of severe rheumatoid arthritis in a treatment-naive subject having a CRP level of >3 mg/L, wherein said compound is to be administered with methotrexate (MTX).
  • MTX methotrexate
  • said rheumatoid arthritis is rheumatoid arthritis with a CDAI score > 22; such as severe rheumatoid arthritis with a CDAI > 22.
  • said rheumatoid arthritis is highly active rheumatoid arthritis. In some embodiments said rheumatoid arthritis is high disease activity rheumatoid arthritis.
  • said rheumatoid arthritis is rheumatoid arthritis with a DAS28 score of above 5.1 ; such as severe rheumatoid arthritis with a DAS28 score of above 5.1.
  • the present disclosure provides a compound of formula (I), including tautomeric and stereoisomeric forms thereof, or a pharmaceutically acceptable derivative or salt thereof, for use in the treatment of rheumatoid arthritis with a CDAI > 22 in a treatment-naive subject having a CRP level of >3 mg/L, wherein said compound is to be administered with methotrexate (MTX).
  • MTX methotrexate
  • the rheumatoid arthritis is rheumatoid arthritis with active joint disease.
  • the rheumatoid arthritis is rheumatoid arthritis with a CDAI > 22 with active joint disease.
  • the rheumatoid arthritis is early rheumatoid arthritis with active joint disease.
  • the subject with rheumatoid arthritis tests positive for rheumatoid factor and/or anti-cyclic citrullinated peptide (CCP) IgG antibodies prior to the treatment.
  • CCP citrullinated peptide
  • said subject is diagnosed with rheumatoid arthritis within about 6 months prior to treatment.
  • said subject is diagnosed with rheumatoid arthritis within about 6 months prior to treatment initiation.
  • Prior to treatment initiation and ‘prior to treatment’ is used interchangeably herein, and refers to diagnosis prior to the treatment (or use) of the present disclosure.
  • MTX methotrexate
  • MTX methotrexate
  • MTX methotrexate
  • said subject is diagnosed with rheumatoid arthritis within about 1 month prior to treatment initiation, within about 2 months prior to treatment initiation, within about 3 months prior to treatment initiation, within about 4 months prior to treatment initiation, within about 5 months prior to treatment initiation, or within about 6 months prior to treatment initiation.
  • said subject is diagnosed with rheumatoid arthritis 0 to 6 months prior to treatment initiation, such as 0 to 1 , 1 to 2, 2 to 3, 3 to 4, 4 to 5, 5 to 6 months prior to treatment initiation.
  • said subject was diagnosed with rheumatoid arthritis less than about 6 months prior to treatment initiation; such as less than about 1 month prior to treatment initiation, such as less than about 2 months prior to treatment initiation, such as less than about 3 months prior to treatment initiation, such as less than about 4 months prior to treatment initiation, such as less than about 5 months prior to treatment initiation, such as less than about 6 months prior to treatment initiation.
  • said subject is diagnosed with rheumatoid arthritis within about 6 months prior to treatment initiation. In a preferred embodiment said subject is diagnosed with rheumatoid arthritis less than about 6 months prior to treatment initiation. 6 months correlates roughly to about 180 to 200 days. In some embodiment said subject is diagnosed with rheumatoid arthritis within about 180 to 200 days prior to treatment initiation.
  • 6 months correlates roughly to about 26 weeks.
  • said subject is diagnosed with rheumatoid arthritis within about 26 weeks prior to treatment initiation.
  • RA rheumatoid arthritis
  • efficacy of medical treatment of the subject can be assessed by a number of different clinical score systems, e.g. the DAS28 score, the CDAI score and the ACR-score.
  • blood markers of inflammation e.g. Erythrocyte sedimentation rate (ESR or sed rate) that indirectly measures the degree of inflammation present in the body of the subject, and the c-reactive protein test that measures the level of C-reactive protein (CRP) in the blood of the subject
  • ESR Erythrocyte sedimentation rate
  • CRP C-reactive protein
  • questionnaires e.g. the Health Assessment Questionnaire Disability Index (HAQ-DI, which assesses subject function) & Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)
  • Imaging techniques such as X-ray imaging, ultrasound imaging, and magnetic resonance imaging (MRI).
  • the use according to the present disclosure results in improved physical function in the subject as determined by the Health Assessment Questionnaire Disability Index (HAQ-DI).
  • HAQ-DI Health Assessment Questionnaire Disability Index
  • the use according to the present disclosure results in improved function in the subject as determined by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue). In one embodiment, the use according to the present disclosure results in partial or complete remission of one or more arthritis symptoms.
  • FACIT-Fatigue Functional Assessment of Chronic Illness Therapy-Fatigue
  • the use according to the present disclosure reduces joint inflammation.
  • the use according to the present disclosure reduces the level of C- reactive protein (CRP).
  • CRP C- reactive protein
  • the use according to the present disclosure reduces the number of tender joints and/or reduces the number of swollen joints.
  • the ACR American College of Rheumatology Criteria is a standard criterion to measure the effectiveness of various arthritis medications or treatments in clinical trials for RA.
  • the ACR response rates ACR20, ACR50, and ACR70 are defined as >20%, >50% and >70% improvement, respectively, in swollen and tender joint counts (SJC/TJC) and 3 of the following 5 assessments: Patient’s Global Assessment of Disease Activity, Physician’s Global Assessment of Disease Activity, Patient’s Assessment of Pain, Health Assessment Questionnaire (HAQ-DI), and C-Reactive Protein (CRP).
  • SJC/TJC swollen and tender joint counts
  • HAQ-DI Health Assessment Questionnaire
  • C-Reactive Protein C-Reactive Protein
  • the ACR-score is improved by the treatment of the present disclosure.
  • the present therapy result in a >20%, a >50% or >70% improvement in ACR response rates.
  • the use according to the present disclosure improves ACR20. In one embodiment, the use according to the present disclosure increases the proportion of patients achieving 20% improvement in ACR.
  • the use according to the present disclosure achieves an ACR20 response rate of at least 60%, such as at least 65%, such as at least 70%, such as at least 75%, such as at least 80%.
  • An ACR20 response rate of at least 60% means that 60% of subjects achieved the ACR20 response rate.
  • the use according to the present disclosure achieves an ACR20 response rate of 60% to 85%; such as of 60% to 65%, such as of 65% to 70%, such as of 70% to 75%, such as of 75% to 80%, such as of 80% to 85%.
  • the use according to the present disclosure achieves an ACR20 response rate of 60% to 80%.
  • the use according to the present disclosure achieves an ACR20 response rate of about 70.6 %, such as of about 70%.
  • the use according to the present disclosure achieves an ACR20 response rate of about 82.1 %, such as of about 82%, such as of 80 to 85%.
  • the use according to the present disclosure achieves the indicated ACR20 response rates by 12 weeks of treatment, such as by week 12.
  • the DAS28 score is a measure of disease activity in rheumatoid arthritis (RA). DAS stands for 'disease activity score' and the number 28 refers to the 28 joints that are examined in this assessment.
  • the DAS28 is a composite score derived from 4 of the above measures. This ‘28’ version is a simplification of the original DAS score, which requires 44 joints to be counted. Other versions of the DAS28 allow the CRP to be used instead of the ESR, or the omission of either.
  • the DAS28-CRP part of the many DAS scores for RA, is very useful to make an objective, reproducible and comparable assessment of the rheumatoid arthritis activity. DAS28-CRP in particular takes into account the following items:
  • TJC28 The number of tender joints (0-28).
  • CRP The C-Reactive Protein level (in mg/l).
  • the 28 tender or swollen joint scores target the same joints (shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints and the knees).
  • the computation of the score can be done through the following equation:
  • DAS2S CRP 0.56 * TJC2S + 0.28 * jSJC2S + 0.36 * ln(C ?P + 1) + 0.014 * GH + 0.96
  • remission is considered achieved if the score is between 0 and ⁇ 2.6.
  • Low disease activity corresponds to 2.6 to ⁇ 3.2.
  • Moderate disease activity is between 3.2 and ⁇ 5.1 , while high disease activity is strictly above 5.1.
  • the present disclosure provides a compound of formula (I) as defined herein in combination with MTX for use in the treatment of severe rheumatoid arthritis, wherein the DAS28 is determined for the subject prior to and after treatment, wherein the treatment results in a reduced DAS28 score, such as wherein the treatment results in a DAS28 score below 5.1 , such as 5.0 or less, such as 4.8 or less, such as 4.6 or less, such as 4.4 or less, such as 4.2 or less, such as 4.0 or less, such as 3.8 or less, such as 3.6 or less, such as 3.4 or less, such as 3.2 or less, such as 3.0 or less, such as 2.8 or less, such as 2.6 or less, such as 2.4 or less, such as 2.2 or less, such as 2.0 or less, such as 1.8 or less, such as 1.6 or less, such as wherein the treatment results in a DAS28 score below 5.1 , below 3.2, more or below 2.6.
  • said subject’s DAS28 score during and/or after treatment is reduced to between 3.2 and ⁇ 5.1 (moderate disease activity), such as reduced to between 2.6 to ⁇ 3.2 (low disease activity), such as reduced to between 0 and ⁇ 2.6 (remission).
  • the use according to the present disclosure results in a reduction in DAS28 score of at least 1 .3 points, such as at least 1.4 points, such as at least 1.5 points, such as at least 1.6 points, such as at least 1.7 points, such as at least 1.8 points, such as at least 1.9 points. In one embodiment, the use according to the present disclosure results in a reduction in DAS28 score of 1.3 to 2.0 points; such as 1.3 to 1.4 points, such as 1.4 to 1.5 points, such as 1.5 to 1.6 points, such as 1.6 to 1.7 points, such as 1.7 to 1.8 points, such as 1.8 to 1.9 points, such as 1.9 to 2.0 points.
  • the use according to the present disclosure achieves the indicated results by 12 weeks of treatment, such as by week 12.
  • TJC Tender 28-Joint Count (shoulders, elbows, wrists, MCPs, PIPs including thumb IP, knees);
  • PGA Patient Global Disease Activity (patient’s self-assessment of overall RA disease activity on a scale 0-100 where 100 is maximal activity);
  • IGA Physician’s Global Disease Activity (evaluator’s assessment of the subject’s overall RA disease activity on a scale 0-100 where 100 is maximal activity)
  • the subjects CDAI score is reduced by the treatment of the present disclosure by 5 points or more, such as 10 points or more, such as 15 point or more.
  • the CDAI score is reduced by the treatment of the present disclosure by at least 15 points, such as at least 16 points, such as at least 17 points, such as at least 18 points, such as at least 19 points, such as at least 20 points, such as at least 21 points, such as at least 22 points, such as at least 23 points, such as at least 24 points.
  • the CDAI score is reduced by the treatment of the present disclosure by at 15 to 25 points, such as 15 to 16 points, such as 16 to 17 points, such as 17 to 18 points, such as 18 to 19 points, such as 19 to 20 points, such as 20 to 21 points, such as 21 to 22 points, such as 22 to 23 points, such as 23 to 24 points, such as 24 to 25 points.
  • the use according to the present disclosure achieves the indicated results by 12 weeks of treatment, such as by 12 weeks.
  • the HAQ-DI Health Assessment Questionnaire Disability Index
  • the HAQ-DI has 8 sections: dressing, arising, eating, walking, hygiene, reach, grip, and activities. There are 2 or 3 questions in each section- Scoring within each section is from 0 (without any difficulty) to 3 (unable to do). For each section the score given to that section is the worst score within the section, i.e., if one question is scored 1 and another 2, then the score for the section is 2. In addition, if an aide or device is used or if help is required from another individual, then the minimum score for that section is 2. The 8 scores of the 8 sections are summed and divided by 8. The result is the DI.
  • the compound of the present disclosure provides for an average decrease in the Health Assessment Questionnaire Disability Index (HAQ-DI) of at least about 0.3, such as at least about 0.4, such as at least about 0.5, such as at least about 0.6, such as at least about 0.65, such as at least about 0.7.
  • HAQ-DI Health Assessment Questionnaire Disability Index
  • the compound of the present disclosure provides for an average decrease in the HAQ-DI of about 0.3 to 0.7; such as about 0.3 to 0.65; such as about 0.3 to 0.4, such as about 0.4 to 0.5, such as about 0.5 to 0.6, such as about 0.6 to 0.65, such as about 0.6 to 0.7.
  • the use according to the present disclosure achieves the indicated average decrease in their HAQ-DI score by 12 weeks of treatment, such as by 12 weeks.
  • the MRI techniques used measure the peak enhancement and rate of enhancement of a contrast agent as indicators of synovial inflammation. Comparing the 12 weeks MRI with the Baseline MRI the AP1189-treated group showed a larger reduction in both mean peak enhancement (3.8 ml vs 1.2 ml) and mean initial rate of enhancement (0.06 ml/sec vs 0.01 ml/sec) compared to the placebo indicating a greater reduction in in inflammation intensity.
  • the compound of the disclosure reduces mean peak enhancement of a contrast by at least 1.0 ml, such as by at least 1.2 ml, such as by more than 1.2 ml, such as by at least 1.5 ml, such as by at least 2.0 ml, such as by at least 2.5 ml, such as by at least 3.0 ml, such as by at least 3.5 ml, such as by at least 3.8 ml, for example at week 12 compared to baseline.
  • the compound of the disclosure reduces the rate of enhancement of a contrast agent by at least 0.02 ml/sec, such as reduced by at least 0.03 ml/sec, such as reduced by at least 0.04 ml/sec, such as reduced by at least 0.05 ml/sec, such as reduced by at least 0.06 ml/sec, for example at week 12 compared to baseline.
  • the use according to the present disclosure reduces MR I -assessed tender joints of about 5.3. In one embodiment the use according to the present disclosure reduces MRI-assessed tender joints of at least 3.0, such as at least 3.5, such as at least 4.0, such as at least 4.5, such as at least 5.0, such as at least 5.3.
  • the use according to the present disclosure reduces MRI- assessed tender joints of 3.0 to 3.5, such as 3.4 to 4.0, such as 4.0 to 4.5, such as 4.5 to 5.0, such as 5.0 to 5.5.
  • the use according to the present disclosure reduces MRI-assessed swollen joints of about 6.4. In one embodiment the use according to the present disclosure reduces MRI-assessed swollen joints of at least 3.8, such as at least 3.9, such as at least 4.0, such as at least 4.5, such as at least 5.0, such as at least 5.5, such as at least 6.0, such as at least 6.4. In one embodiment the use according to the present disclosure reduces MRI-assessed swollen joints of 3.8 to 4.0, such as 4.0 to 4.5, such as 4.5 to 5.0, such as 5.0 to 5.5, such as 5.5 to 6.0, such as at 6.0 to 6.5.
  • C4M is a marker of synovial collagen 4 degradation.
  • Lower levels of C4M mean a lower rate of Collagen 4 degradation which is believed to be a marker for lower synovial inflammation.
  • C4M was significantly reduced in the AP1189-treated group, whereas it was unchanged in the placebo group.
  • the treatment of the present disclosure reduces C4M. In one embodiment the treatment of the present disclosure reduces the rate of Collagen 4 degradation. In one embodiment the treatment of the present disclosure reduces synovial inflammation.
  • the use according to the present disclosure achieves the reduced C4M by 12 weeks of treatment, such as by 12 weeks.
  • the compound of the disclosure is selected from the group consisting of ⁇ 3-[1-(2-nitrophenyl)-1 H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidine and (E)-/V-frans- ⁇ 3-[1-(2-nitrophenyl)-1 H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidine, or a pharmaceutically acceptable salt thereof.
  • said compound is ⁇ 3-[1-(2-nitrophenyl)- 1 H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidine, or a pharmaceutically acceptable derivative thereof.
  • said compound is (E)-/V-frans- ⁇ 3-[1-(2- nitrophenyl)-1 H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidine, or a pharmaceutically acceptable derivative thereof.
  • a pharmaceutically acceptable derivative is a pharmaceutically acceptable salt.
  • said compound is (E)-/V-frans- ⁇ 3-[1-(2- nitrophenyl)-1 H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidine, or a pharmaceutically acceptable salt thereof.
  • a pharmaceutically acceptable derivative thereof is a pharmaceutically acceptable salt of an inorganic acid or an organic acid.
  • a pharmaceutically acceptable salt of an organic acid is selected from the group consisting of: formic acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, propionic acid, benzoic acid, cinnamic acid, citric acid, fumaric acid, glycolic acid, lactic acid such as L-lactic acid or DL-lactic acid, maleic acid, malic acid, malonic acid, mandelic acid such as DL-mandelic acid, oxalic acid, picric acid, pyruvic acid, salicylic acid, succinic acid, methanesulfonic acid, ethanesulfonic acid, tartaric acid, ascorbic acid, pamoic acid, bismethylene salicylic acid, ethanedisulfonic acid, gluconic acid, citraconic acid, aspartic acid, stearic acid, palmitic acid, EDTA, glycolic acid, p-aminobenzoic acid, glutamic
  • said organic acid is acetic acid, succinic acid, tartaric acid or propionic acid.
  • organic acid is acetic acid. In a particular embodiment said organic acid is succinic acid.
  • a pharmaceutically acceptable salt of an inorganic acid according to the present disclosure is selected from the group consisting of: hydrochloric acid, hydrobromic acid, hydroiodic acid, phosphoric acid, sulphuric acid and nitric acid.
  • said compound is selected from the group consisting of: (E)-N-[1-(2-nitrophenyl)-1-H-pyrrole-2-yl-allylideneamino]-guanidinium acetate, including tautomeric and stereoisomeric forms thereof;
  • the compound is ⁇ 3-[1-(2-nitrophenyl)-1 H-pyrrol-2-yl]-allylidene ⁇ - aminoguanidine, for example (E)-N-trans- ⁇ 3-[1-(2-nitrophenyl)-1 H-pyrrol-2-yl]- allylidenej-aminoguanidine, or a pharmaceutically acceptable salt thereof, such as (E)- N-trans- ⁇ 3-[1-(2-nitrophenyl)-1 H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidinium acetate or (E)-N-trans- ⁇ 3-[1-(2-nitrophenyl)-1 H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidinium succinate.
  • said compound is selected from the group consisting of ⁇ 3-[1-(2-nitrophenyl)-1 H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidinium acetate and (E)-/V-frans- ⁇ 3-[1-(2-nitrophenyl)-1 H-pyrrol-2-yl]-allylidene ⁇ - aminoguanidinium acetate.
  • said compound is selected from the group consisting of ⁇ 3-[1-(2-nitrophenyl)-1 H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidinium succinate and (E)-/V-frans- ⁇ 3-[1-(2-nitrophenyl)-1 H-pyrrol-2-yl]-allylidene ⁇ - aminoguanidinium succinate.
  • the pharmaceutically acceptable salt of AP1189 according to the present disclosure is a crystalline or polymorphic form of AP1189 acetate.
  • the compound of the present disclosure is a crystalline form of N- ⁇ 3-[1-(2-nitrophenyl)-1 H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidinium acetate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu Ka radiation at 11.5 ⁇ 0.2, 23.5 ⁇ 0.2, and 27.0 ⁇ 0.2.
  • said crystalline form further exhibits one or more X-ray lines (2- theta values) in a powder diffraction pattern when measured using Cu Ka radiation selected from the group consisting of 11.7 ⁇ 0.2, 15.6 ⁇ 0.2, and 24.8 ⁇ 0.2.
  • said MTX is selected from the group consisting of methotrexate (systemic), methotrexate (oral), methotrexate tablet, methotrexate oral solution, methotrexate (injection), methotrexate sodium, Methotrexate LPF Sodium, Trexall (Xatmep), Rheumatrex, Rasuvo, Otrexup, Alltrex, Beltrax, Biotrexate, Caditrex, Carditrex, Cytotrex, Dermotrex, Folitrax, Hl-Trex, Imutrex, Merex, Methocip, Methorex, Methotrexate, Metorex, Metrex, Mexate, MTX-Korea, Neotrexate, Nidtrex, Oncotrex, Onotrex, Plastomet, Remtrex, Rextop, Roxate, Tevatrex, Throtex, Trex, Thixilem, Vibzi and Zexate.
  • methotrexate systemic
  • the dosage used herewith is calculated as AP1189 free base, unless otherwise indicated.
  • about 120 mg (E)-N-trans- ⁇ 3-[1-(2-nitrophenyl)-1 H-pyrrol-2-yl]- allylidenej-aminoguanidinium acetate corresponds to about 100 mg (E)-N-trans- ⁇ 3-[1- (2-nitrophenyl)-1 H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidine (free base), as used in the examples.
  • a dosage of about 41.5 mg free base corresponds to about 50 mg of the acetate salt
  • a dosage of about 83 mg free base corresponds to about 100 mg of the acetate salt of the compound of formula (I) according to the present disclosure.
  • a formulation comprising about 100 mg AP1189 free base will comprise about 120 mg AP1189 acetate (120.482 or 120.5 mg).
  • a formulation comprising about 100 mg AP1189 free base will comprise about 140 mg AP1189 succinate.
  • a compound of formula (I) for use in the treatment of rheumatoid arthritis in a subject with a C-Reactive Protein (CRP) level of >3 mg/L, wherein said compound is to be administered with methotrexate (MTX), and wherein said compound is administered at a dosage of about 10 mg to 500 mg daily; such as about 10 mg to 15 mg, such as about 15 mg to 20 mg, such as about 20 mg to 25 mg, such as about 25 mg to 50 mg, such as about 50 to 75 mg, such as about 75 to 100 mg, such as about 100 mg to 125 mg, such as about 125 mg to 150 mg, such as about 150 mg to 175 mg, such as about 175 to 200 mg, such as about 200 to 225 mg, such as about 225 mg to 250 mg, such as about 250 mg to 275 mg, such as about 275 mg to 300 mg, such as about 300 to 350 mg, such as about 350 to 400 mg, such as about 400 mg to 450
  • said compound is administered at a daily dosage (calculated as the free base) of about 41.5 mg to about 50 mg, such as about 50 mg to about 83 mg, such as about 83 mg to about 100 mg, such as about 100 mg to about 125 mg, such as about 125 mg to about 150 mg, such as about 150 mg to about 175 mg, such as about 175 mg to about 200 mg, such as about 200 mg to about 225 mg, such as about 225 mg to about 250 mg, such as about 250 mg to about 300 mg.
  • a daily dosage (calculated as the free base) of about 41.5 mg to about 50 mg, such as about 50 mg to about 83 mg, such as about 83 mg to about 100 mg, such as about 100 mg to about 125 mg, such as about 125 mg to about 150 mg, such as about 150 mg to about 175 mg, such as about 175 mg to about 200 mg, such as about 200 mg to about 225 mg, such as about 225 mg to about 250 mg, such as about 250 mg to about 300 mg.
  • said compound is administered at a daily dosage of about 25 mg to about 400 mg, such as about 50 mg to about 300 mg, such as about 50 mg to about 250 mg, such as about 50 mg to about 200 mg, such as about 75 mg to about 150 mg (calculated as the free base).
  • said compound is administered at a daily dosage of about 10 mg to about 100 mg, such as about 10 mg to about 20 mg, such as about 20 mg to about 25 mg, such as about 25 mg to about 50 mg, such as about 50 mg to about 75 mg, such as about 75 mg to about 100 mg (calculated as the free base)
  • a compound of formula (I) for use in the treatment of rheumatoid arthritis in a subject with a C-Reactive Protein (CRP) level of >3 mg/L, wherein said compound is to be administered with methotrexate (MTX), and wherein said compound is administered at a dosage of about 100 mg daily, such as once daily, wherein said dosage is calculated as the free base.
  • CRP C-Reactive Protein
  • MTX methotrexate
  • a dosage of about 100 mg daily, and a daily dosage of about 100 mg, are used interchangeably.
  • said compound is administered at a dosage of about 100 mg daily (calculated as the free base), which dosage is administered in a once daily dosage. In one embodiment said compound is administered at a dosage of about 100 mg daily (calculated as the free base), which dosage is divided into a twice daily or three times daily dosage.
  • a compound of formula (I) for use in the treatment of rheumatoid arthritis in a subject with a C-Reactive Protein (CRP) level of >3 mg/L, wherein said compound is to be administered with methotrexate (MTX), and wherein said compound is administered at a dosage of about 10 to 100 mg daily, such as once daily, wherein said dosage is calculated as the free base.
  • CRP C-Reactive Protein
  • MTX methotrexate
  • said compound is (E)-N-trans- ⁇ 3-[1-(2-nitrophenyl)-1 H- pyrrol-2-yl]-allylidene ⁇ -aminoguanidinium acetate.
  • said compound is (E)-N-trans- ⁇ 3-[1-(2-nitrophenyl)-1 H-pyrrol-2-yl]- allylidenej-aminoguanidinium acetate, and is administered at a daily dosage of about 100 mg daily (calculated as the free base), such as a once daily dosage.
  • said compound is (E)-N-trans- ⁇ 3-[1-(2-nitrophenyl)-1 H-pyrrol-2-yl]- allylidenej-aminoguanidinium acetate, and is administered at a daily dosage of about 120 mg daily (calculated as acetate salt form), such as a once daily dosage.
  • methotrexate is administered in an amount or dosage of about 5 mg to about 30 mg once weekly.
  • methotrexate is administered in an amount or dosage of about 5 mg to about 30 mg once weekly on the same week day.
  • One per week and once weekly are used interchangeably herein. Once per week means once every 7 days, preferably on the same week day.
  • MTX is administered at a dosage of about 5 mg to about 10 mg once per week, such as about 5 mg to about 15 mg once per week, such as about 5 mg to about 20 mg once per week, such as about 5 mg to about 25 mg once per week, such as about 5 mg to about 30 mg once per week, such as about 7.5 mg to about 10 mg once per week, such as about 7.5 mg to about 15 mg once per week, such as about 7.5 mg to about 20 mg once per week, such as about 7.5 mg to about 25 mg once per week, such as about 7.5 mg to about 30 mg once per week, such as about 10 mg to about 15 mg once per week, such as about 10 mg to about 20 mg once per week, such as about 10 mg to about 25 mg once per week, such as about 10 mg to about 30 mg once per week, such as about 15 mg to about 20 mg once per week, such as about 15 mg to about 25 mg once per week, such as about 15 mg to about 30 mg once per week, such as about 20 mg to about 25 mg once per week, such as about 20 mg to about
  • said MTX is administered at a dosage of about 5 mg to about 7.5 mg once per week, 7.5 mg to about 10 mg once per week such as about 10 mg to about 15 mg once per week, such as about 15 mg to about 20 mg once per week, such as about 20 mg to about 25 mg once per week, such as about 25 mg to about 30 mg once per week.
  • methotrexate (MTX) is administered at a dosage of about 5 mg to about 30 mg once weekly. In one embodiment of the present disclosure, methotrexate (MTX) is administered at a dosage of about 7.5 mg to about 25 mg once weekly. In one embodiment of the present disclosure, methotrexate (MTX) is administered at a dosage of about 10 mg to about 25 mg once weekly. In one embodiment of the present disclosure, methotrexate (MTX) is administered at a dosage of about 10 mg to about 20 mg once weekly.
  • methotrexate is administered at a dosage of no more than 20 mg once weekly.
  • the methotrexate (MTX) is administered at a dosage of about 5 mg once weekly, such as about 7.5 mg once weekly, such as about 10 mg once weekly, such as about 12.5 mg once weekly, such as about 15 mg once weekly, such as about 17.5 mg once weekly, such as about 20 mg once weekly, such as about 25 mg once weekly, such as about 30 mg once weekly.
  • the methotrexate (MTX) is administered in a weekly dosage or amount of about 5 mg to about 7.5 mg, such as about 7.5 mg to about 10 mg, such as about 10 mg to about 15 mg, such as about 5 mg to about 20 mg, such as about 10 to about 20 mg, such as about 10 to about 25 mg, such as about 15 to about 20 mg.
  • the methotrexate (MTX) or prodrug thereof is administered subcutaneously in an amount or dosage of about 5 to about 30 mg once per week/weekly.
  • Once per week means once every 7 days, preferably on the same week day.
  • the methotrexate (MTX) or prodrug thereof is administered intramuscularly in an amount or dosage of about 5 to about 30 mg once per week/weekly.
  • Once per week means once every 7 days, preferably on the same week day.
  • the methotrexate (MTX) or prodrug thereof is administered in an oral dosage form in an amount or dosage of about 10 to about 25 mg once per week/weekly.
  • Once per week means once every 7 days, preferably on the same week day.
  • MTX or a prodrug thereof is administered once weekly.
  • Commercially available dosage forms of MTX are available, for oral administration or subcutaneous administration. Both dosage forms are to be administered once a week, preferably on the same week day.
  • the compound of the disclosure is administered daily, preferable once daily, and MTX is administered once weekly.
  • the compound of the disclosure is administered at a daily dosage of 50 mg to about 250 mg (calculated as the free base), such as once daily, and said MTX is administered at a dosage of 5 to 30 mg once weekly.
  • the compound of the disclosure is administered at a dosage of between about 50 and about 250 mg per day (calculated as the free base) and said MTX is administered at a dosage between about 10 and about 25 mg once weekly, such as wherein said compound is administered at a dosage of between about 50 and about 200 mg per day (calculated as the free base) and said MTX is administered at a dosage between about 10 and about 25 mg once weekly, such as wherein said compound is administered at a dosage of between about 75 and about 200 mg per day (calculated as the free base) and said MTX is administered at a dosage between about 10 and about 25 mg once weekly, such as wherein said compound is administered at a dosage of between about 75 and about 175 mg per day (calculated as the free base) and said MTX is administered at a dosage between about 10 and about 25 mg once weekly, such as wherein said compound is administered at a dosage of between about 75 and about 150 mg per day (calculated as the free base) and said MTX is administered at a dosage between a dosage
  • the compound of the disclosure is administered at a dosage of about 10 to about 200 mg per day (calculated as the free base) and said MTX is administered at a dosage of about 7.5 to about 20 mg once weekly, such as wherein said compound is administered at a dosage of about 10 to about 100 mg per day (calculated as the free base) and said MTX is administered at a dosage of about 7.5 to about 20 mg once weekly such as about 7.5 to about 15 mg once weekly.
  • the subject with rheumatoid arthritis is about to start up-titration with methotrexate.
  • said up-titration with MTX starts with a low dosage and gradually increases the dosage over time.
  • the subject with rheumatoid arthritis starts up-titration with methotrexate at 7.5 mg. In one embodiment the subject with rheumatoid arthritis starts up-titration with methotrexate at 10 mg. In one embodiment the subject with rheumatoid arthritis starts up-titration with methotrexate at 12.5 mg. In one embodiment the subject with rheumatoid arthritis starts up-titration with methotrexate at 15 mg.
  • the subject with rheumatoid arthritis ends up-titration with methotrexate at 10 mg. In one embodiment the subject with rheumatoid arthritis ends up-titration with methotrexate at 12.5 mg. In one embodiment the subject with rheumatoid arthritis ends up-titration with methotrexate at 15 mg. In one embodiment the subject with rheumatoid arthritis ends up-titration with methotrexate at 17.5 mg. In one embodiment the subject with rheumatoid arthritis ends up-titration with methotrexate at 20 mg. In one embodiment the subject with rheumatoid arthritis ends up-titration with methotrexate at 25 mg.
  • the present disclosure provides a compound of formula (I), including tautomeric and stereoisomeric forms thereof, or a pharmaceutically acceptable derivative or salt thereof, for use in the treatment of rheumatoid arthritis in a treatment-naive subject having a CRP level of >3 mg/L, optionally wherein said rheumatoid arthritis is moderate to severe RA, optionally wherein said subject is diagnosed with rheumatoid arthritis within 6 months prior to treatment initiation, wherein said compound is to be administered with methotrexate (MTX), wherein said compound is administered at a daily dosage of about 50 to about 250 mg (calculated as the free base), such as about 50 mg to 200 mg, such as about 75 to 150 mg, such as about 100 mg, and said MTX is administered at a dosage of about 10 to about 30 mg once weekly, such as about 10 to about 25 mg once weekly, such as about 10 to about 20 mg once weekly, such as about 10 to about 15 mg once weekly; such as about 10 mg, about 12.5
  • said folic acid is administered at about 1 to 10 mg folic acid per week, such as about 5 mg folic acid per week, such as at least 5 mg folic acid per week. In one embodiment said folic acid is administered once weekly. In one embodiment said folic acid is administered in daily dosages.
  • the compounds for use according to the present disclosure including a compound of formula (I) including tautomeric and stereoisomeric forms thereof, or a pharmaceutically acceptable derivative thereof, and methotrexate (MTX), may be provided in any suitable formulation.
  • MTX is formulated for oral administration, such as in the form of tablets, capsules or oral solutions or suspensions.
  • the compound of formula (I) including tautomeric and stereoisomeric forms thereof, and pharmaceutically acceptable salts thereof is formulated for oral administration, such as in the form of tablets, capsules, or oral solutions or suspensions.
  • the compound of formula (I) including tautomeric and stereoisomeric forms thereof, and pharmaceutically acceptable salts thereof, is formulated for immediate release.
  • AP1189 has previously been formulated as an enteric coated tablet and later as an alkaline suspension. It has recently been demonstrated that a subset of the pharmaceutically acceptable salts of AP1189, including AP1189 in its acetate salt and succinate salt forms, are highly soluble at low pH and hence do not require protection from gastric pH, allowing the use also of solid oral formulations targeting release in the gastric compartment such as immediate release solid oral formulations. Such formulation are disclosed in WO 2022/268825, which is incorporated by reference herein in its entirety.
  • a unit dosage form comprising a compound of formula (I) including tautomeric and stereoisomeric forms thereof, and pharmaceutically acceptable salts thereof, for the uses disclosed herein.
  • an oral formulation comprising a compound of formula (I) including tautomeric and stereoisomeric forms thereof, and pharmaceutically acceptable salts thereof, for the uses disclosed herein.
  • the pharmaceutically acceptable salt of AP1189 is a crystalline or polymorphic form of a pharmaceutically acceptable salt of AP1189 selected from the group consisting of: AP1189 acetate, AP1189 succinate, the DL-mandelic acid salt of AP1189, the hippuric acid salt of AP1189, the L-lactic acid salt of AP1189, the besylate salt of AP1189, the oxoglutarate salt of AP1189, the formic acid salt of AP1189, the DL-lactic acid salt of AP1189, the glutaric acid salt of AP1189, the adipic acid salt of AP1189 and the nitrate salt of AP1189.
  • Polymorphic forms are prepared and disclosed in WO 2022/268814, the disclosure of which is incorporated by reference herewith.
  • said oral formulation delivers or releases said compound to the gastric compartment (or stomach), such as primarily or predominantly delivers or releases said compound to the gastric compartment (or stomach).
  • said oral formulation delivers or releases not less than about 65% to about 80% of said compound in the gastric compartment; such as not less than about 65% of said compound, such as not less than about 70%, such as not less than about 75%, such as not less than about 80%, such as not less than about 85%, such as not less than about 90%, such as not less than about 95% of said compound in the gastric compartment.
  • said oral formulation immediately releases said compound in the gastric compartment. In one embodiment said oral formulation releases said compound in the gastric compartment for gastric absorption of said compound. In one embodiment said oral formulation releases said compound in the gastric compartment for absorption of said compound over the gastric mucus layer. In one embodiment said oral formulation is designed for gastric delivery. In one embodiment said oral formulation is designed for gastric release. In one embodiment said oral formulation is designed for gastric absorption.
  • said oral formulation is a solid oral formulation. In one embodiment said solid oral formulation is a solid oral dosage form. In one embodiment said solid oral dosage form is an immediate release solid oral dosage form.
  • said oral formulation is a tablet. In one embodiment said solid oral formulation is a tablet. In one embodiment said solid oral dosage form is a tablet.
  • a solid oral formulation, solid oral dosage form or tablet comprising a compound of formula (I) as disclosed herein, wherein not less than about 65% to about 80% of said compound is dissolved into solution in the gastric compartment.
  • a solid oral formulation, solid oral dosage form or tablet comprising a compound of formula (I) as disclosed herein, wherein not less than about 65%, such as not less than about 70%, such as not less than about 75%, such as not less than about 80%, such as not less than about 85%, such as not less than about 90%, such as not less than about 95% of said compound is dissolved into solution in the gastric compartment.
  • an oral formulation such as a solid oral formulation, such as an immediate-release solid oral formulation, comprising a compound of formula (I) as disclosed herein, wherein not less than about 65% to about 80% of said compound is dissolved into solution in about 15 minutes.
  • an oral formulation such as a solid oral formulation, such as an immediate-release solid oral formulation, comprising a compound of formula (I) as disclosed herein, wherein not less than about 65% to about 80% of said compound is dissolved into solution in about 15 minutes at a pH of about 1 to 3, such as a pH of about 0.5 to 3.5; such as a pH of about 0.5 to 1 , such as a pH of about 1 to 1.5, such as a pH of about 1.5 to 2, such as a pH of about 2 to 2.5, such as a pH of about 2.5 to 3, such as a pH of about 3 to 3.5.
  • an oral formulation such as a solid oral formulation, such as an immediate-release solid oral formulation, comprising a compound of formula (I) as disclosed herein, wherein not less than about 65% to about 80% of said compound is dissolved into solution in about 15 minutes at a pH of about 1.2.
  • an oral formulation such as a solid oral formulation, such as an immediate-release solid oral formulation, comprising a compound of formula (I) as disclosed herein, wherein not less than about 65% to about 80% of the of the nominal dose of said compound is released in about 15 minutes in a monograph dissolution test.
  • an oral formulation such as a solid oral formulation, such as an immediate-release solid oral formulation, comprising a compound of formula (I) as disclosed herein, wherein not less than about 80% of said compound is dissolved into solution in about 10 to 15 minutes, such as at a pH of about 1.2.
  • dissolution is measured using a USP 2 paddle equipment at 37 °C at a rotation speed of 50 rpm, as disclosed in WO 2022/268825.
  • an oral formulation such as a solid oral formulation, such as an immediate-release solid oral formulation or dosage form, comprising a compound of formula (I) as disclosed herein, wherein not less than 80% of the compound is dissolved into aqueous solution in 15 minutes at a pH of 1 to 3, such as at a pH of about 1.2, using a USP 2 paddle equipment at 37 °C at a rotation speed of 50 rpm.
  • not less than 80% of the compound is dissolved into aqueous solution in 15 minutes at pH 1 (0.1 N HCI), using a USP 2 paddle equipment at 37 °C at a rotation speed of 50 rpm.
  • not less than 80% of the compound is dissolved into aqueous solution in 15 minutes at a pH of 1 to 3, such as at a pH of about 1.2, using a USP 2 paddle equipment at 37 °C at a rotation speed of 50 rpm; wherein the dissolution media consist of 500 ml 0.1 N HCI + 50 ml of water.
  • the compound is (E)-N-[1-(2-nitrophenyl)-1-H-pyrrole-2-yl- allylideneamino]-guanidinium acetate, including tautomeric and stereoisomeric forms thereof.
  • an oral formulation such as a solid oral formulation, such as an immediate-release solid oral formulation, comprising a compound of formula (I) as disclosed herein, wherein the disintegration time of said oral formulation such as solid oral formulation is from 14 minute to 10 minutes, such as 14 minute to 1 minute, such as 1 to 2 minutes, such as 2 to 3 minutes, such as 3 to 4 minutes, such as 4 to 5 minutes, such as 5 to 6 minutes, such as 6 to 7 minutes, such as 7 to 8 minutes, such as 8 to 9 minutes, such as 9 to 10 minutes.
  • the solid oral dosage form comprises a compound of formula (I) as defined herein at a dosage from about 25 mg to about 650 mg per dosage form, such as about 25 mg, such as about 50 mg, such as about 100 mg, such as about 150 mg, such as about 200 mg, such as about 250 mg, such as about 300 mg, such as about 350 mg, such as about 400 mg, such as about 450 mg, such as about 500 mg, such as about 550 mg, such as about 600 mg, such as about 650 mg compound (calculated as the free base).
  • a dosage from about 25 mg to about 650 mg per dosage form such as about 25 mg, such as about 50 mg, such as about 100 mg, such as about 150 mg, such as about 200 mg, such as about 250 mg, such as about 300 mg, such as about 350 mg, such as about 400 mg, such as about 450 mg, such as about 500 mg, such as about 550 mg, such as about 600 mg, such as about 650 mg compound (calculated as the free base).
  • the study population consisted of patients with Rheumatoid Arthritis with high disease activity defined as having a clinical disease activity index (CDAI) > 22 at the start-up of first line treatment with the disease modulation anti rheumatoid drug MTX. At the same day of initiation of MTX patients were allocated to co-treatment with AP1189 or matched placebo. The compound was given once daily as tablet at the 100 mg (free base) dose level.
  • CDAI clinical disease activity index
  • CDAI clinical disease activity index
  • the primary efficacy readout was the ability to reach a 20% reduction in disease activity as evaluated by American College of Rheumatology (ACR) scoring index (ACR20). To reach 20% reduction in disease activity the ACR20 should be reached.
  • ACR American College of Rheumatology scoring index
  • ACR20 To reach 20% reduction in disease activity the ACR20 should be reached.
  • ACR20 In order to reach ACR20 a patient has a reduction of a minimum of 20% in tender and swollen joints based on standardized evaluation of 68 predefined joints evaluated for tenderness and evaluation of 66 joints for swollenness. If a reduction of 20% in tender and swollen joint over the 12-week treatment period was identified, additionally 3 out of 5 measurement scores should also show a minimum 20% reduction. The 5 scores of which 3 should show a 20% reduction to full-fill the requirement to qualify for ACR20 was 1. the patient's evaluation of global disease activity using a visual analogue score (PGA(VAS));
  • CRP C-reactive protein
  • the percentage of-AP1189 treated patients with systemic inflammation was higher than in the placebo-treated patients.
  • a subset of the patients with C-reactive peptide above 3 mg/L were diagnosed with RA less than 6 months before initiation of treatment, i.e. before the start-up of MTX treatment and co-treatment with AP1189/placebo.
  • the AP1189-treated patient group included 28 patients diagnosed within 6 months of treatment initiation, and the placebo-treated group included 27 patients diagnosed within 6 months of treatment initiation. In these patients the percentage of patients reaching ACR20 was as follows:

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une thérapie comprenant un composé de formule (I), tel que AP1189, et du méthotrexate pour le traitement de la polyarthrite rhumatoïde chez des sujets ayant une inflammation systémique active.
PCT/EP2024/075319 2023-12-11 2024-09-11 Traitement de la sous-population de patients atteints de polyarthrite rhumatoïde Pending WO2025124760A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23215545 2023-12-11
EP23215545.7 2023-12-11

Publications (1)

Publication Number Publication Date
WO2025124760A1 true WO2025124760A1 (fr) 2025-06-19

Family

ID=89168323

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/075319 Pending WO2025124760A1 (fr) 2023-12-11 2024-09-11 Traitement de la sous-population de patients atteints de polyarthrite rhumatoïde

Country Status (1)

Country Link
WO (1) WO2025124760A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020229297A1 (fr) 2019-05-10 2020-11-19 Synact Pharma Aps Traitement combiné d'une maladie arthritique
WO2022268825A1 (fr) 2021-06-21 2022-12-29 Synact Pharma Aps Sels de phényl pyrrole aminoguanidine et formulations associées
WO2023094692A1 (fr) * 2021-11-29 2023-06-01 Synact Pharma Aps Traitement de la polyarthrite rhumatoïde

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020229297A1 (fr) 2019-05-10 2020-11-19 Synact Pharma Aps Traitement combiné d'une maladie arthritique
WO2022268825A1 (fr) 2021-06-21 2022-12-29 Synact Pharma Aps Sels de phényl pyrrole aminoguanidine et formulations associées
WO2022268814A1 (fr) 2021-06-21 2022-12-29 Synact Pharma Aps Sels de phényl pyrrole aminoguanidine et polymorphes de sels de phényl pyrrole aminoguanidinium
WO2023094692A1 (fr) * 2021-11-29 2023-06-01 Synact Pharma Aps Traitement de la polyarthrite rhumatoïde

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. PHARM. SCI., vol. 66, 1977, pages 2
NEHRING SARA M ET AL: "C Reactive Protein - StatPearls - NCBI Bookshelf", 10 July 2023 (2023-07-10), XP093225435, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/books/NBK441843/> *

Similar Documents

Publication Publication Date Title
Schmidt Alvimopan (ADL 8-2698) is a novel peripheral opioid antagonist
Jakobs et al. Buprenorphine or procaine for pain relief in acute pancreatitis A prospective randomized study
JP6169644B2 (ja) 低頻度酢酸グラチラマー治療
US6242421B1 (en) Methods for preventing and treating Alzheimer&#39;s disease
ES2476368T3 (es) Tratamiento de la artritis reumatoide con una combinación de laquinimod y metotrexato
US12303489B2 (en) Combination treatment of arthritic disease
US7879870B2 (en) Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists
JP2013166765A5 (fr)
JP2020519594A (ja) フェンフルラミンを用いるドゥーゼ症候群の治療方法
EA021303B1 (ru) Способы лечения или профилактики рвоты с помощью агентов, усиливающих секрецию гормона роста
JP2009537563A (ja) Ｔａｃｉ融合分子を使用する自己免疫疾患を治療するための方法
KR20150013658A (ko) 다발성 경화증을 치료하기 위한 고용량의 라퀴니모드의 용도
JP2017128578A (ja) 腎疾患の治療におけるモノおよびジカルボン酸のアミドの使用
JPH09323927A (ja) 慢性閉塞性動脈硬化症の治療のためのカルニチン誘導体含有薬剤
KR20190064583A (ko) Chs-131로 다발성 경화증의 치료
Hüseyin et al. Cyclosporin treatment of anal and perianal lesions associated with Crohn’s disease
JP2024516795A (ja) エベロリムスおよびアムセネストラントを含む組合せ物
WO2025124760A1 (fr) Traitement de la sous-population de patients atteints de polyarthrite rhumatoïde
US20250032449A1 (en) Treatment of rheumatoid arthritis
Silver et al. Livedo reticularis in Parkinson's disease patients treated with amantadine hydrochloride
Bergen Jr et al. Hypocholesteremic effect in man of benzmalecene: An inhibitor of cholesterol biosynthesis
JP2024133112A (ja) インターロイキン－１受容体アンタゴニスト融合タンパク質の送達による炎症状態の治療
US20250387365A1 (en) Combination Treatment Of Arthritic Disease
CA2309395A1 (fr) Methodes de prevention et de traitement de la maladie d&#39;alzheimer
HK40047132B (en) Combination treatment of arthritic disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24766066

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)